Early clinical milestone unlikely to move shares near term; focus on interim safety data after first 5 patients for potential catalyst. Historical stock reaction to similar updates has been weak.
Price Chart
Executive Summary
Alpha Tau announced the first patient treated in Italy with its Alpha DaRT therapy for pancreatic cancer, a feasibility and safety study at the University of Verona's Pancreas Institute. The milestone expands the company's global pancreatic cancer program but represents an early-stage clinical update with no near-term revenue implications.
Key Facts
- First Alpha DaRT pancreatic cancer patient treated in Italy under protocol CTP-PANC-03
- Study plans to enroll up to 15 patients with locally advanced pancreatic cancer at a single center
- First Alpha DaRT pancreatic protocol to permit both endoscopic ultrasound (EUS) and percutaneous delivery
- Follows first European patient treated in April 2026 in France's ACAPELLA trial and ongoing U.S. IMPACT trial
Financial Impact
No financial data provided; zero-revenue clinical-stage company with no near-term commercialization impact
Risk Factors
- Pancreatic cancer trials have high failure rate; feasibility/safety data may not translate to efficacy
- Company has significant operating losses and requires additional funding; dilution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-053086 |
| Document: ea0289554-6k_alphatau.htm | 0001213900-26-053086 |
| Document: 0001213900-26-053086-index-headers.html | 0001213900-26-053086 |
| Document: 0001213900-26-053086-index.html | 0001213900-26-053086 |
| Document: 0001213900-26-053086.txt | 0001213900-26-053086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access